Edwin Asturias
Concepts (483)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Guatemala | 55 | 2026 | 349 | 4.020 |
Why?
| | Vaccines | 9 | 2026 | 389 | 3.600 |
Why?
| | Vaccination | 21 | 2026 | 1449 | 3.060 |
Why?
| | Influenza, Human | 11 | 2026 | 640 | 2.660 |
Why?
| | Microcephaly | 5 | 2024 | 106 | 2.580 |
Why?
| | Zika Virus Infection | 6 | 2024 | 174 | 2.540 |
Why?
| | Advisory Committees | 4 | 2026 | 228 | 2.280 |
Why?
| | Rural Population | 19 | 2026 | 677 | 2.200 |
Why?
| | Poliovirus Vaccine, Inactivated | 6 | 2018 | 27 | 2.020 |
Why?
| | Poliomyelitis | 8 | 2018 | 35 | 1.810 |
Why?
| | Health Policy | 4 | 2026 | 399 | 1.740 |
Why?
| | Poliovirus Vaccine, Oral | 7 | 2018 | 25 | 1.670 |
Why?
| | Infant | 50 | 2026 | 10114 | 1.660 |
Why?
| | Virus Shedding | 11 | 2026 | 54 | 1.640 |
Why?
| | Zika Virus | 5 | 2024 | 137 | 1.630 |
Why?
| | Dengue | 6 | 2024 | 92 | 1.460 |
Why?
| | Child Development | 5 | 2025 | 481 | 1.410 |
Why?
| | Policy Making | 4 | 2026 | 83 | 1.380 |
Why?
| | Viral Vaccines | 4 | 2025 | 107 | 1.320 |
Why?
| | Streptococcus pneumoniae | 5 | 2025 | 187 | 1.160 |
Why?
| | Community-Acquired Infections | 4 | 2026 | 179 | 1.130 |
Why?
| | Pneumonia, Pneumococcal | 3 | 2025 | 48 | 1.110 |
Why?
| | Caliciviridae Infections | 2 | 2018 | 18 | 1.050 |
Why?
| | Norovirus | 2 | 2018 | 22 | 1.040 |
Why?
| | Poliovirus | 6 | 2018 | 73 | 1.020 |
Why?
| | Child, Preschool | 34 | 2026 | 11913 | 1.010 |
Why?
| | Gastroenteritis | 2 | 2017 | 63 | 0.980 |
Why?
| | Haemophilus Vaccines | 5 | 2016 | 29 | 0.980 |
Why?
| | Reminder Systems | 2 | 2019 | 149 | 0.950 |
Why?
| | Dengue Virus | 6 | 2024 | 62 | 0.920 |
Why?
| | Hepatitis B Vaccines | 5 | 2026 | 43 | 0.910 |
Why?
| | Humans | 114 | 2026 | 146342 | 0.910 |
Why?
| | Family Characteristics | 9 | 2026 | 203 | 0.890 |
Why?
| | Growth Disorders | 2 | 2023 | 89 | 0.880 |
Why?
| | Text Messaging | 2 | 2019 | 188 | 0.880 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 125 | 0.840 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2023 | 1408 | 0.840 |
Why?
| | Fever | 2 | 2017 | 322 | 0.840 |
Why?
| | Public Health | 4 | 2026 | 574 | 0.820 |
Why?
| | Immunization Schedule | 5 | 2017 | 187 | 0.810 |
Why?
| | Streptococcal Vaccines | 1 | 2023 | 7 | 0.790 |
Why?
| | Immunization | 4 | 2023 | 376 | 0.790 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2026 | 438 | 0.770 |
Why?
| | Child | 32 | 2026 | 22693 | 0.770 |
Why?
| | Meningitis, Meningococcal | 1 | 2022 | 6 | 0.750 |
Why?
| | Neisseria meningitidis | 1 | 2022 | 23 | 0.740 |
Why?
| | Meningococcal Infections | 1 | 2022 | 26 | 0.740 |
Why?
| | Prospective Studies | 20 | 2026 | 8123 | 0.740 |
Why?
| | Cell Phone | 3 | 2019 | 83 | 0.730 |
Why?
| | Infant, Newborn | 20 | 2026 | 6460 | 0.720 |
Why?
| | Meningococcal Vaccines | 1 | 2022 | 57 | 0.720 |
Why?
| | Female | 69 | 2026 | 79499 | 0.700 |
Why?
| | Antibodies, Neutralizing | 5 | 2026 | 348 | 0.670 |
Why?
| | Neurodevelopmental Disorders | 1 | 2024 | 239 | 0.660 |
Why?
| | Streptococcal Infections | 1 | 2023 | 179 | 0.650 |
Why?
| | Serogroup | 5 | 2025 | 46 | 0.640 |
Why?
| | Virus Diseases | 1 | 2022 | 219 | 0.620 |
Why?
| | Endpoint Determination | 1 | 2020 | 84 | 0.620 |
Why?
| | Product Surveillance, Postmarketing | 2 | 2025 | 74 | 0.600 |
Why?
| | Rural Health Services | 2 | 2019 | 139 | 0.600 |
Why?
| | Diarrhea | 5 | 2023 | 190 | 0.590 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2025 | 81 | 0.590 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2016 | 28 | 0.590 |
Why?
| | Immunity, Humoral | 3 | 2017 | 121 | 0.590 |
Why?
| | Influenza Vaccines | 3 | 2021 | 544 | 0.580 |
Why?
| | Male | 56 | 2026 | 73396 | 0.580 |
Why?
| | Contraception | 4 | 2022 | 170 | 0.570 |
Why?
| | Adolescent Health | 1 | 2019 | 38 | 0.560 |
Why?
| | Hospitalization | 9 | 2026 | 2475 | 0.560 |
Why?
| | Immunity, Mucosal | 2 | 2016 | 97 | 0.550 |
Why?
| | Arbovirus Infections | 1 | 2018 | 20 | 0.550 |
Why?
| | Sentinel Surveillance | 2 | 2017 | 48 | 0.550 |
Why?
| | Community Health Services | 2 | 2019 | 229 | 0.540 |
Why?
| | Haemophilus influenzae type b | 2 | 2014 | 12 | 0.540 |
Why?
| | Pleural Effusion | 3 | 2026 | 59 | 0.520 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 881 | 0.520 |
Why?
| | Carrier State | 3 | 2014 | 80 | 0.520 |
Why?
| | Urban Health Services | 1 | 2017 | 68 | 0.510 |
Why?
| | Immunogenicity, Vaccine | 1 | 2017 | 42 | 0.500 |
Why?
| | Multiplex Polymerase Chain Reaction | 3 | 2025 | 56 | 0.490 |
Why?
| | Pregnancy | 16 | 2026 | 7230 | 0.480 |
Why?
| | Community Health Planning | 1 | 2016 | 38 | 0.470 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 45 | 0.470 |
Why?
| | Neonatal Screening | 1 | 2017 | 185 | 0.460 |
Why?
| | Schools | 1 | 2019 | 436 | 0.460 |
Why?
| | Physician Assistants | 1 | 2017 | 102 | 0.450 |
Why?
| | Family Planning Services | 3 | 2022 | 93 | 0.450 |
Why?
| | Population Health | 1 | 2016 | 44 | 0.450 |
Why?
| | Adolescent | 26 | 2026 | 22557 | 0.450 |
Why?
| | Population Surveillance | 2 | 2025 | 481 | 0.440 |
Why?
| | Anemia, Hemolytic | 1 | 2015 | 21 | 0.440 |
Why?
| | Immunization Programs | 4 | 2026 | 194 | 0.440 |
Why?
| | Latin America | 5 | 2018 | 96 | 0.440 |
Why?
| | Parents | 3 | 2023 | 1394 | 0.440 |
Why?
| | Young Adult | 22 | 2026 | 14330 | 0.430 |
Why?
| | Consumer Product Safety | 1 | 2016 | 80 | 0.430 |
Why?
| | Mobile Applications | 1 | 2017 | 196 | 0.430 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2014 | 13 | 0.430 |
Why?
| | Herpes Zoster | 2 | 2015 | 318 | 0.430 |
Why?
| | Castleman Disease | 1 | 2014 | 16 | 0.420 |
Why?
| | Sexual Behavior | 1 | 2019 | 490 | 0.420 |
Why?
| | Exanthema | 1 | 2015 | 86 | 0.420 |
Why?
| | Haemophilus Infections | 1 | 2014 | 45 | 0.420 |
Why?
| | Adult | 36 | 2026 | 41087 | 0.400 |
Why?
| | Needs Assessment | 2 | 2016 | 404 | 0.400 |
Why?
| | Adolescent Behavior | 1 | 2019 | 486 | 0.400 |
Why?
| | Brain Diseases | 1 | 2015 | 159 | 0.400 |
Why?
| | Bacterial Capsules | 2 | 2014 | 33 | 0.400 |
Why?
| | Calcitonin | 1 | 2013 | 26 | 0.390 |
Why?
| | Influenza A Virus, H3N2 Subtype | 2 | 2026 | 50 | 0.390 |
Why?
| | Receptors, Interleukin-6 | 1 | 2013 | 49 | 0.390 |
Why?
| | Health Behavior | 1 | 2019 | 802 | 0.380 |
Why?
| | Global Health | 1 | 2016 | 403 | 0.370 |
Why?
| | Antibodies, Bacterial | 2 | 2014 | 147 | 0.370 |
Why?
| | Protein Precursors | 1 | 2013 | 127 | 0.370 |
Why?
| | Bacterial Infections | 2 | 2013 | 247 | 0.360 |
Why?
| | Caregivers | 1 | 2021 | 1080 | 0.360 |
Why?
| | Polymerase Chain Reaction | 2 | 2026 | 1031 | 0.360 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2025 | 266 | 0.350 |
Why?
| | Feces | 8 | 2018 | 496 | 0.350 |
Why?
| | Intestines | 4 | 2018 | 351 | 0.350 |
Why?
| | Chikungunya Fever | 2 | 2025 | 82 | 0.340 |
Why?
| | Diet | 1 | 2019 | 1273 | 0.330 |
Why?
| | Anti-Bacterial Agents | 5 | 2026 | 1942 | 0.330 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2014 | 992 | 0.320 |
Why?
| | Contraceptive Agents | 2 | 2021 | 65 | 0.320 |
Why?
| | Intestinal Mucosa | 1 | 2016 | 666 | 0.310 |
Why?
| | Antigens, Viral | 2 | 2024 | 186 | 0.310 |
Why?
| | Antibodies, Viral | 8 | 2026 | 689 | 0.310 |
Why?
| | Urban Population | 4 | 2026 | 497 | 0.300 |
Why?
| | Saccharum | 3 | 2020 | 77 | 0.300 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 6 | 0.290 |
Why?
| | United States | 13 | 2026 | 16136 | 0.290 |
Why?
| | Surveys and Questionnaires | 5 | 2021 | 6073 | 0.290 |
Why?
| | Cross-Sectional Studies | 7 | 2026 | 5899 | 0.280 |
Why?
| | Nasopharynx | 2 | 2025 | 72 | 0.280 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 829 | 0.280 |
Why?
| | Biomarkers | 2 | 2025 | 4340 | 0.280 |
Why?
| | Agriculture | 2 | 2020 | 94 | 0.270 |
Why?
| | Dengue Vaccines | 2 | 2018 | 11 | 0.270 |
Why?
| | Influenza A virus | 2 | 2026 | 120 | 0.270 |
Why?
| | Delivery, Obstetric | 2 | 2019 | 164 | 0.270 |
Why?
| | Malnutrition | 1 | 2009 | 87 | 0.260 |
Why?
| | World Health Organization | 3 | 2017 | 104 | 0.260 |
Why?
| | Cohort Studies | 7 | 2025 | 6077 | 0.260 |
Why?
| | Appointments and Schedules | 2 | 2019 | 97 | 0.250 |
Why?
| | Postpartum Period | 4 | 2026 | 377 | 0.240 |
Why?
| | Emergency Service, Hospital | 3 | 2026 | 2363 | 0.240 |
Why?
| | Primary Health Care | 1 | 2017 | 1776 | 0.240 |
Why?
| | RNA, Viral | 2 | 2021 | 693 | 0.240 |
Why?
| | Seroconversion | 2 | 2017 | 48 | 0.240 |
Why?
| | Acute Disease | 3 | 2019 | 1038 | 0.240 |
Why?
| | Empyema | 1 | 2026 | 8 | 0.230 |
Why?
| | Neonatal Sepsis | 1 | 2026 | 9 | 0.230 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2026 | 40 | 0.220 |
Why?
| | Glomerular Filtration Rate | 2 | 2020 | 745 | 0.220 |
Why?
| | Blood Culture | 1 | 2025 | 27 | 0.220 |
Why?
| | Infant Mortality | 1 | 2026 | 127 | 0.220 |
Why?
| | Azithromycin | 1 | 2026 | 101 | 0.220 |
Why?
| | Risk Factors | 12 | 2026 | 10921 | 0.210 |
Why?
| | Anthropometry | 2 | 2022 | 204 | 0.210 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2026 | 104 | 0.210 |
Why?
| | Vaccines, Conjugate | 2 | 2022 | 60 | 0.210 |
Why?
| | Viral Load | 2 | 2024 | 526 | 0.210 |
Why?
| | Chikungunya virus | 1 | 2025 | 81 | 0.210 |
Why?
| | Head | 1 | 2025 | 125 | 0.200 |
Why?
| | Bacteremia | 2 | 2025 | 218 | 0.200 |
Why?
| | Meningitis, Haemophilus | 1 | 2003 | 6 | 0.200 |
Why?
| | Viruses | 2 | 2023 | 165 | 0.200 |
Why?
| | Culex | 1 | 2023 | 14 | 0.200 |
Why?
| | Ritonavir | 1 | 2024 | 76 | 0.200 |
Why?
| | Antiviral Agents | 3 | 2026 | 779 | 0.200 |
Why?
| | Sepsis | 3 | 2026 | 669 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2025 | 141 | 0.190 |
Why?
| | Cost of Illness | 1 | 2026 | 323 | 0.190 |
Why?
| | Streptococcus pyogenes | 1 | 2023 | 41 | 0.190 |
Why?
| | Saliva | 1 | 2025 | 256 | 0.190 |
Why?
| | Sequence Analysis, DNA | 1 | 2026 | 771 | 0.190 |
Why?
| | Antimicrobial Stewardship | 1 | 2025 | 136 | 0.190 |
Why?
| | Aedes | 1 | 2023 | 67 | 0.190 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 234 | 0.190 |
Why?
| | Aspirin | 1 | 2026 | 405 | 0.190 |
Why?
| | Postnatal Care | 2 | 2021 | 76 | 0.180 |
Why?
| | Psychometrics | 3 | 2021 | 712 | 0.180 |
Why?
| | Vomiting | 1 | 2023 | 131 | 0.180 |
Why?
| | Incidence | 4 | 2022 | 2936 | 0.180 |
Why?
| | Seasons | 2 | 2025 | 540 | 0.180 |
Why?
| | Seroepidemiologic Studies | 2 | 2022 | 171 | 0.180 |
Why?
| | Vital Signs | 1 | 2022 | 39 | 0.180 |
Why?
| | Travel | 3 | 2015 | 134 | 0.180 |
Why?
| | Cough | 1 | 2023 | 123 | 0.180 |
Why?
| | Regression Analysis | 2 | 2022 | 999 | 0.180 |
Why?
| | Vaccines, Attenuated | 2 | 2025 | 129 | 0.180 |
Why?
| | Propensity Score | 1 | 2024 | 376 | 0.180 |
Why?
| | Premature Birth | 1 | 2026 | 390 | 0.170 |
Why?
| | Ambulatory Care | 2 | 2026 | 628 | 0.170 |
Why?
| | Herpesvirus 3, Human | 2 | 2015 | 342 | 0.170 |
Why?
| | Meningitis, Bacterial | 2 | 2015 | 52 | 0.170 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 1036 | 0.170 |
Why?
| | Escherichia coli Vaccines | 2 | 2013 | 4 | 0.170 |
Why?
| | Vaccines, Combined | 3 | 2024 | 49 | 0.170 |
Why?
| | Quality Improvement | 5 | 2022 | 1354 | 0.170 |
Why?
| | Sensitivity and Specificity | 5 | 2026 | 1998 | 0.170 |
Why?
| | Attitude | 1 | 2023 | 253 | 0.170 |
Why?
| | Middle Aged | 15 | 2026 | 36619 | 0.170 |
Why?
| | Respiration, Artificial | 1 | 2026 | 711 | 0.160 |
Why?
| | Malaria Vaccines | 1 | 2020 | 11 | 0.160 |
Why?
| | Respiratory Tract Infections | 1 | 2025 | 403 | 0.160 |
Why?
| | Health Promotion | 2 | 2019 | 786 | 0.160 |
Why?
| | Cesarean Section | 2 | 2019 | 230 | 0.160 |
Why?
| | Yellow fever virus | 1 | 2020 | 4 | 0.160 |
Why?
| | Birth Intervals | 1 | 2020 | 23 | 0.160 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2015 | 69 | 0.160 |
Why?
| | Outpatients | 1 | 2024 | 440 | 0.160 |
Why?
| | Midwifery | 1 | 2022 | 70 | 0.160 |
Why?
| | Yellow Fever | 1 | 2020 | 9 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2021 | 3416 | 0.160 |
Why?
| | Health Services Accessibility | 2 | 2020 | 1107 | 0.160 |
Why?
| | Maternal Health Services | 1 | 2022 | 100 | 0.160 |
Why?
| | Vaccination Refusal | 1 | 2020 | 62 | 0.150 |
Why?
| | Absenteeism | 1 | 2020 | 51 | 0.150 |
Why?
| | Cesarean Section, Repeat | 1 | 2019 | 11 | 0.150 |
Why?
| | Intensive Care, Neonatal | 1 | 2020 | 41 | 0.150 |
Why?
| | Colorado | 4 | 2026 | 4595 | 0.150 |
Why?
| | Agricultural Workers' Diseases | 1 | 2020 | 29 | 0.150 |
Why?
| | Vaginal Birth after Cesarean | 1 | 2019 | 27 | 0.150 |
Why?
| | Language Tests | 1 | 2019 | 24 | 0.150 |
Why?
| | Drug Discovery | 1 | 2020 | 154 | 0.150 |
Why?
| | Contraception Behavior | 1 | 2020 | 108 | 0.150 |
Why?
| | Bayes Theorem | 3 | 2026 | 426 | 0.150 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2020 | 334 | 0.150 |
Why?
| | Maternal Age | 1 | 2019 | 129 | 0.140 |
Why?
| | Communication | 1 | 2026 | 980 | 0.140 |
Why?
| | Language Development Disorders | 1 | 2019 | 40 | 0.140 |
Why?
| | Motor Skills | 1 | 2020 | 103 | 0.140 |
Why?
| | Arboviruses | 1 | 2018 | 14 | 0.140 |
Why?
| | Thinness | 1 | 2019 | 100 | 0.140 |
Why?
| | Entamoeba histolytica | 1 | 2018 | 9 | 0.140 |
Why?
| | Puerto Rico | 1 | 2018 | 64 | 0.140 |
Why?
| | Pregnancy in Adolescence | 1 | 2019 | 78 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1064 | 0.140 |
Why?
| | Farmers | 1 | 2019 | 71 | 0.130 |
Why?
| | Socioeconomic Factors | 2 | 2025 | 1327 | 0.130 |
Why?
| | Heat Stress Disorders | 1 | 2019 | 84 | 0.130 |
Why?
| | Treatment Refusal | 1 | 2018 | 99 | 0.130 |
Why?
| | Vulnerable Populations | 1 | 2019 | 178 | 0.130 |
Why?
| | Mothers | 3 | 2022 | 772 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 153 | 0.130 |
Why?
| | Aged, 80 and over | 3 | 2026 | 8391 | 0.130 |
Why?
| | Educational Status | 1 | 2019 | 466 | 0.130 |
Why?
| | Pneumococcal Infections | 2 | 2016 | 104 | 0.120 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 109 | 0.120 |
Why?
| | Health Surveys | 1 | 2019 | 511 | 0.120 |
Why?
| | Poliovirus Vaccines | 1 | 2016 | 6 | 0.120 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2018 | 78 | 0.120 |
Why?
| | Aged | 10 | 2026 | 26432 | 0.120 |
Why?
| | Occupational Health | 2 | 2018 | 212 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2020 | 295 | 0.120 |
Why?
| | Child Behavior | 1 | 2019 | 234 | 0.120 |
Why?
| | Myelitis | 1 | 2018 | 107 | 0.120 |
Why?
| | Panama | 1 | 2016 | 11 | 0.120 |
Why?
| | Colombia | 1 | 2016 | 41 | 0.120 |
Why?
| | Dominican Republic | 1 | 2016 | 29 | 0.120 |
Why?
| | Neoplasms | 2 | 2016 | 2954 | 0.120 |
Why?
| | Risk-Taking | 1 | 2019 | 321 | 0.120 |
Why?
| | Peru | 1 | 2016 | 61 | 0.120 |
Why?
| | Community Health Nursing | 1 | 2016 | 63 | 0.120 |
Why?
| | Databases, Factual | 3 | 2019 | 1493 | 0.120 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 39 | 0.120 |
Why?
| | Sanitation | 1 | 2016 | 56 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 366 | 0.120 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2016 | 49 | 0.110 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 146 | 0.110 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2015 | 17 | 0.110 |
Why?
| | HIV Infections | 2 | 2014 | 3215 | 0.110 |
Why?
| | Water Supply | 1 | 2016 | 90 | 0.110 |
Why?
| | Learning | 1 | 2020 | 446 | 0.110 |
Why?
| | Analysis of Variance | 1 | 2018 | 1298 | 0.110 |
Why?
| | Chickenpox | 1 | 2016 | 83 | 0.110 |
Why?
| | Single-Blind Method | 1 | 2016 | 313 | 0.110 |
Why?
| | Enterovirus Infections | 1 | 2018 | 175 | 0.110 |
Why?
| | Typhoid Fever | 1 | 2015 | 12 | 0.110 |
Why?
| | Occupational Exposure | 1 | 2019 | 356 | 0.110 |
Why?
| | Health Information Systems | 1 | 2015 | 16 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 287 | 0.110 |
Why?
| | Data Collection | 1 | 2018 | 650 | 0.110 |
Why?
| | Patient Preference | 1 | 2017 | 226 | 0.110 |
Why?
| | Education, Nursing | 1 | 2016 | 92 | 0.110 |
Why?
| | Community Participation | 1 | 2016 | 128 | 0.110 |
Why?
| | Antibody Affinity | 1 | 2014 | 60 | 0.110 |
Why?
| | Disease Outbreaks | 1 | 2018 | 422 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2015 | 302 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 96 | 0.100 |
Why?
| | Malaria | 1 | 2015 | 73 | 0.100 |
Why?
| | Vincristine | 1 | 2014 | 148 | 0.100 |
Why?
| | Biomedical Research | 1 | 2020 | 729 | 0.100 |
Why?
| | Cyclophosphamide | 1 | 2014 | 275 | 0.100 |
Why?
| | Overweight | 1 | 2019 | 614 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2921 | 0.100 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 96 | 0.100 |
Why?
| | History, 21st Century | 1 | 2014 | 224 | 0.100 |
Why?
| | Enterotoxins | 1 | 2013 | 89 | 0.100 |
Why?
| | Universities | 1 | 2016 | 451 | 0.100 |
Why?
| | Rituximab | 1 | 2014 | 208 | 0.100 |
Why?
| | Prednisone | 1 | 2014 | 229 | 0.100 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2013 | 39 | 0.100 |
Why?
| | History, 20th Century | 1 | 2014 | 330 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2020 | 640 | 0.100 |
Why?
| | Bacterial Toxins | 1 | 2013 | 110 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2021 | 3647 | 0.100 |
Why?
| | Students | 1 | 2019 | 649 | 0.100 |
Why?
| | Developing Countries | 3 | 2026 | 312 | 0.100 |
Why?
| | Causality | 1 | 2013 | 128 | 0.090 |
Why?
| | Education, Medical | 1 | 2016 | 274 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2015 | 166 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2019 | 947 | 0.090 |
Why?
| | Lymphocytes | 1 | 2014 | 379 | 0.090 |
Why?
| | Time Factors | 5 | 2026 | 7109 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1591 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1792 | 0.090 |
Why?
| | Doxorubicin | 1 | 2014 | 416 | 0.090 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 200 | 0.090 |
Why?
| | Lymph Nodes | 1 | 2014 | 511 | 0.090 |
Why?
| | Program Evaluation | 1 | 2016 | 952 | 0.080 |
Why?
| | Hypertension | 1 | 2020 | 1272 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2019 | 866 | 0.080 |
Why?
| | ROC Curve | 2 | 2026 | 617 | 0.080 |
Why?
| | Kidney | 1 | 2018 | 1498 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2014 | 784 | 0.080 |
Why?
| | Immunization, Secondary | 1 | 2010 | 94 | 0.070 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 162 | 0.070 |
Why?
| | Escherichia coli | 1 | 2013 | 832 | 0.070 |
Why?
| | Decision Support Systems, Clinical | 1 | 2013 | 279 | 0.070 |
Why?
| | Clinical Competence | 1 | 2017 | 1272 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2026 | 2070 | 0.070 |
Why?
| | Physicians | 1 | 2017 | 955 | 0.070 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 43 | 0.070 |
Why?
| | Creatinine | 2 | 2020 | 511 | 0.060 |
Why?
| | Penicillins | 1 | 2007 | 65 | 0.060 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2007 | 77 | 0.060 |
Why?
| | Asphyxia Neonatorum | 1 | 2026 | 20 | 0.060 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2025 | 7 | 0.060 |
Why?
| | Stillbirth | 1 | 2026 | 83 | 0.060 |
Why?
| | Kenya | 1 | 2026 | 129 | 0.060 |
Why?
| | Contact Tracing | 1 | 2025 | 26 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 790 | 0.060 |
Why?
| | Hepatitis B | 1 | 2026 | 66 | 0.060 |
Why?
| | Influenza B virus | 1 | 2025 | 47 | 0.060 |
Why?
| | Cities | 2 | 2016 | 140 | 0.060 |
Why?
| | Prevalence | 2 | 2025 | 2861 | 0.060 |
Why?
| | Basic Reproduction Number | 1 | 2025 | 6 | 0.050 |
Why?
| | Neuropsychological Tests | 2 | 2020 | 1149 | 0.050 |
Why?
| | DNA, Bacterial | 1 | 2026 | 319 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1998 | 0.050 |
Why?
| | Mexico | 3 | 2013 | 233 | 0.050 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2025 | 83 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2786 | 0.050 |
Why?
| | Mosquito Vectors | 1 | 2023 | 32 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2003 | 67 | 0.050 |
Why?
| | Chickens | 1 | 2023 | 169 | 0.050 |
Why?
| | Hot Temperature | 1 | 2026 | 396 | 0.050 |
Why?
| | China | 1 | 2024 | 280 | 0.050 |
Why?
| | Administration, Oral | 1 | 2026 | 872 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2020 | 11821 | 0.050 |
Why?
| | Cross Reactions | 1 | 2022 | 130 | 0.050 |
Why?
| | Gestational Age | 1 | 2026 | 990 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1707 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2026 | 901 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1763 | 0.040 |
Why?
| | Mammals | 1 | 2023 | 288 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2020 | 3017 | 0.040 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 253 | 0.040 |
Why?
| | Administration, Cutaneous | 2 | 2013 | 128 | 0.040 |
Why?
| | Hospitals | 2 | 2016 | 738 | 0.040 |
Why?
| | Paraguay | 1 | 2020 | 3 | 0.040 |
Why?
| | Sri Lanka | 1 | 2020 | 8 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 846 | 0.040 |
Why?
| | Endemic Diseases | 1 | 2020 | 34 | 0.040 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 33 | 0.040 |
Why?
| | Translations | 1 | 2020 | 14 | 0.040 |
Why?
| | Home Health Nursing | 1 | 2019 | 13 | 0.040 |
Why?
| | Parity | 1 | 2019 | 113 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2015 | 561 | 0.040 |
Why?
| | Specific Gravity | 1 | 2019 | 13 | 0.040 |
Why?
| | Prenatal Care | 1 | 2022 | 310 | 0.040 |
Why?
| | Child Language | 1 | 2019 | 21 | 0.040 |
Why?
| | Bacteria | 2 | 2019 | 766 | 0.040 |
Why?
| | Translating | 1 | 2019 | 46 | 0.040 |
Why?
| | Rural Health | 1 | 2019 | 87 | 0.040 |
Why?
| | Electrolytes | 1 | 2019 | 52 | 0.040 |
Why?
| | Parasites | 1 | 2019 | 44 | 0.040 |
Why?
| | Dehydration | 1 | 2019 | 59 | 0.040 |
Why?
| | Culturally Competent Care | 1 | 2019 | 66 | 0.030 |
Why?
| | Reproductive Health | 1 | 2019 | 94 | 0.030 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 10 | 0.030 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 188 | 0.030 |
Why?
| | Decision Making | 1 | 2026 | 993 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2019 | 517 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 130 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 143 | 0.030 |
Why?
| | Licensure | 1 | 2017 | 16 | 0.030 |
Why?
| | House Calls | 1 | 2019 | 154 | 0.030 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 245 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 2017 | 82 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2022 | 1135 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2017 | 61 | 0.030 |
Why?
| | Choice Behavior | 1 | 2019 | 179 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 1998 | 102 | 0.030 |
Why?
| | Paralysis | 1 | 2018 | 69 | 0.030 |
Why?
| | Francisella | 1 | 1997 | 2 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 317 | 0.030 |
Why?
| | Registries | 1 | 2026 | 2400 | 0.030 |
Why?
| | Retrospective Studies | 4 | 2020 | 17438 | 0.030 |
Why?
| | Counseling | 1 | 2020 | 406 | 0.030 |
Why?
| | Granulomatous Disease, Chronic | 1 | 1997 | 49 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2017 | 360 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 203 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2020 | 503 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 1997 | 50 | 0.030 |
Why?
| | Enterovirus D, Human | 1 | 2018 | 89 | 0.030 |
Why?
| | Acyclovir | 1 | 2016 | 97 | 0.030 |
Why?
| | Chile | 1 | 2015 | 26 | 0.030 |
Why?
| | Cholestasis | 1 | 1998 | 217 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 399 | 0.030 |
Why?
| | IgG Deficiency | 2 | 2006 | 6 | 0.030 |
Why?
| | IgA Deficiency | 2 | 2006 | 5 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 382 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2016 | 432 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2016 | 130 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2018 | 385 | 0.030 |
Why?
| | Spleen | 1 | 1997 | 503 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 218 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 512 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 678 | 0.030 |
Why?
| | Blood Pressure | 1 | 2021 | 1765 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2092 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 171 | 0.020 |
Why?
| | Europe | 1 | 2013 | 421 | 0.020 |
Why?
| | Checklist | 1 | 2013 | 105 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 486 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1068 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 539 | 0.020 |
Why?
| | Survival Analysis | 1 | 2015 | 1378 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1137 | 0.020 |
Why?
| | Oncology Service, Hospital | 1 | 2011 | 15 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 2092 | 0.020 |
Why?
| | Oseltamivir | 1 | 2011 | 17 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1665 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1486 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2015 | 740 | 0.020 |
Why?
| | El Salvador | 1 | 2010 | 6 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 377 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1512 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2458 | 0.020 |
Why?
| | Animals | 2 | 2023 | 38106 | 0.020 |
Why?
| | Latex Fixation Tests | 1 | 2008 | 4 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2008 | 17 | 0.020 |
Why?
| | Leukocytosis | 1 | 2008 | 31 | 0.020 |
Why?
| | Coma | 1 | 2008 | 39 | 0.020 |
Why?
| | Bacteriological Techniques | 1 | 2008 | 66 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2008 | 88 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2015 | 1468 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 4118 | 0.020 |
Why?
| | Child Day Care Centers | 1 | 2007 | 36 | 0.020 |
Why?
| | Shock | 1 | 2008 | 101 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5439 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3712 | 0.010 |
Why?
| | Ethiopia | 1 | 2006 | 43 | 0.010 |
Why?
| | Microbial Sensitivity Tests | 1 | 2007 | 367 | 0.010 |
Why?
| | Pakistan | 1 | 2006 | 83 | 0.010 |
Why?
| | Algorithms | 1 | 2013 | 1849 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1998 | 3034 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2219 | 0.010 |
Why?
| | Common Variable Immunodeficiency | 1 | 2004 | 26 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 2004 | 36 | 0.010 |
Why?
| | Brazil | 1 | 2004 | 179 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 329 | 0.010 |
Why?
| | United Kingdom | 1 | 2004 | 377 | 0.010 |
Why?
| | Short Bowel Syndrome | 1 | 1998 | 24 | 0.010 |
Why?
| | Bilirubin | 1 | 1998 | 101 | 0.010 |
Why?
| | Liver Failure | 1 | 1998 | 79 | 0.010 |
Why?
| | Abscess | 1 | 1997 | 77 | 0.010 |
Why?
| | Water Microbiology | 1 | 1997 | 87 | 0.010 |
Why?
|
|
Asturias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|